Drugs /

okn-007

Back to Drugs List

Overview

NCI Definition [1]:
A disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.

Clinical Trials

View Clinical Trials for okn-007

Okn-007 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating okn-007, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

Glioblastoma is the most common disease being investigated in okn-007 clinical trials [2].

Drug Details

Synonyms [2]:
pbn derivative okn-007, 2,4-disulfophenyl-tert-butylnitrone, nxy-059, 2,4-disulfonyl pbn, okn 007, 2,4-disulfophenyl-tert-butylnitrone, okn007, 2,4-disulfonyl pbn, 168021-79-2
Drug Target(s) [2]:
SULF2
NCIT ID [1]:
C102983

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.